IP Library › Granted Patent US 11,649,211
Granted Patent B2
US 11,649,211 · App. 17/113,369 · Granted May 16, 2023

Use of quinoline derivatives for the treatment of inflammatory diseases

Inventors: Jamal Tazi (Clapiers, FR); Romain Najman (L'Hay-les-Roses, FR); Florence Mahuteau (Saint Remy les Chevreuses, FR); Didier Scherrer (Castelnau le Lez, FR); Karim Chebli (Frontignan, FR); Michael Hahne (Montpellier, FR)
Assignees: ABIVAX; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; INSTITUT CURIE; UNIVERSITE DE MONTPELLIER
C07D215/38A61K31/47A61K31/4709A61K31/497A61K31/5377C07D401/12C12Q1/6883G01N33/5023G01N33/5055C12Q2600/136C12Q2600/158C12Q2600/178
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,649,211
App. No.
17/113,369
Granted
May 16, 2023
Kind
B2
Abstract

The present disclosure relates to the use of a compound of formula (I) or anyone of its pharmaceutically acceptable salts, in the treatment and/or prevention of an inflammatory disease; wherein: means an aromatic ring wherein V is C or N and when V is N; Q is N or O, provided that R″ does not exist when Q is O; R′ independently represent a hydrogen atom or a group chosen among a (C 1 -C 3 )alkyl group, a halogen atom, a hydroxyl group, a —COOR 1 group, a —NO 2 group, a —NR 1 R 2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C 1 -C 3 )fluoroalkyl group, a —O—P(═O)—(OR 3 )(OR 4 ) group, a (C 1 -C 4 )alkoxy group and a —CN group, and can further be a group chosen among:

Claims (16)

1. A method of treating an inflammatory disease comprising administering 8-chloro-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine, or a pharmaceutically acceptable salt thereof, to a patient in need thereof to treat the inflammatory disease, wherein the inflammatory disease is inflammatory bowel disease, Crohn's disease, or ulcerative colitis.

2. The method of claim 1 , which comprises administering 8-chloro-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine.

3. The method of claim 1 , wherein the inflammatory disease is inflammatory bowel disease.

4. The method of claim 1 , wherein the inflammatory disease is Crohn's disease.

5. The method of claim 1 , wherein the inflammatory disease is ulcerative colitis.

6. The method of claim 2 , wherein the inflammatory disease is inflammatory bowel disease.

7. The method of claim 2 , wherein the inflammatory disease is Crohn's disease.

8. The method of claim 2 , wherein the inflammatory disease is ulcerative colitis.

9. A method of treating an inflammatory disease comprising administering 8-chloro-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine, or a pharmaceutically acceptable salt thereof, to a patient in need thereof to treat the inflammatory disease, wherein the inflammatory disease is arthritis, rheumatoid arthritis, or osteoarthritis.

10. The method of claim 9 , which comprises administering 8-chloro-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine.

11. The method of claim 9 , wherein the inflammatory disease is arthritis.

12. The method of claim 9 , wherein the inflammatory disease is rheumatoid arthritis.

13. The method of claim 9 , wherein the inflammatory disease is osteoarthritis.

14. The method of claim 10 , wherein the inflammatory disease is arthritis.

15. The method of claim 10 , wherein the inflammatory disease is rheumatoid arthritis.

16. The method of claim 10 , wherein the inflammatory disease is osteoarthritis.

Priority Claims (1)
EP 14306164 · Jul 17, 2014 · regional
Continuity (3)
Continuation 16554748 · Aug 29, 2019
Division 15326755
Related Publication 20210087145A1 · Mar 25, 2021
Cited By (1)
US 12,655,171